1. Home
  2. WAL vs DMAC Comparison

WAL vs DMAC Comparison

Compare WAL & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Western Alliance Bancorporation (DE)

WAL

Western Alliance Bancorporation (DE)

HOLD

Current Price

$87.70

Market Cap

8.7B

Sector

Finance

ML Signal

HOLD

Logo DiaMedica Therapeutics Inc.

DMAC

DiaMedica Therapeutics Inc.

HOLD

Current Price

$8.44

Market Cap

428.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WAL
DMAC
Founded
1994
2000
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.7B
428.6M
IPO Year
2005
N/A

Fundamental Metrics

Financial Performance
Metric
WAL
DMAC
Price
$87.70
$8.44
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
14
4
Target Price
$98.93
$15.50
AVG Volume (30 Days)
851.2K
434.0K
Earning Date
01-26-2026
11-12-2025
Dividend Yield
1.73%
N/A
EPS Growth
24.99
N/A
EPS
8.09
N/A
Revenue
$3,189,400,000.00
N/A
Revenue This Year
$16.21
N/A
Revenue Next Year
$9.07
N/A
P/E Ratio
$10.87
N/A
Revenue Growth
9.57
N/A
52 Week Low
$57.05
$3.19
52 Week High
$94.40
$10.42

Technical Indicators

Market Signals
Indicator
WAL
DMAC
Relative Strength Index (RSI) 59.89 53.77
Support Level $82.86 $7.74
Resistance Level $88.09 $8.75
Average True Range (ATR) 1.79 0.41
MACD -0.08 -0.06
Stochastic Oscillator 81.57 68.08

Price Performance

Historical Comparison
WAL
DMAC

About WAL Western Alliance Bancorporation (DE)

Western Alliance Bancorporation is a Las Vegas-based holding company with regional banks operating in Nevada, Arizona, and California. The bank offers retail banking services and focuses on mortgages for retail customers and commercial loans. The company's reportable segments are Commercial segment includes provides commercial banking and treasury management products and services to small and middle-market businesses, specialized banking services to sophisticated commercial institutions and investors within niche industries, as well as financial services to the real estate industry. Consumer Related segment offers both commercial banking services to enterprises in consumer-related sectors and consumer banking services, such as residential mortgage banking and Corporate & Other.

About DMAC DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.

Share on Social Networks: